Evidence map›Paper›PMID 36680228›Full record

ArticleViruses2023

Human Infections with Borna Disease Virus 1 (BoDV-1) Primarily Lead to Severe Encephalitis: Further Evidence from the Seroepidemiological BoSOT Study in an Endemic Region in Southern Germany.

Markus Bauswein, Lisa Eidenschink, Gertrud Knoll, Bernhard Neumann, Klemens Angstwurm, Saida Zoubaa, Markus J Riemenschneider, Benedikt M J Lampl, Matthias Pregler, Hans Helmut Niller and 13 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Structural insights into the dynamic mechanism of bornavirus polymerase.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. [Viral zoonoses in Germany: a One Health perspective].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2023
    Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 4 institutions in 1 country.

Markus BausweinInstitute of Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany.ORCID 0000-0002-2371-5063
Lisa EidenschinkInstitute of Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany.
Gertrud KnollInstitute of Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany.
Bernhard NeumannDepartment of Neurology, Donau-Isar-Klinikum Deggendorf, 94469 Deggendorf, Germany.ORCID 0000-0001-8254-8616
Klemens AngstwurmDepartment of Neurology, University of Regensburg, Bezirksklinikum, 93053 Regensburg, Germany.ORCID 0000-0003-3220-8829
Saida ZoubaaDepartment of Neuropathology, University Hospital Regensburg, 93053 Regensburg, Germany.
Markus J RiemenschneiderDepartment of Neuropathology, University Hospital Regensburg, 93053 Regensburg, Germany.
Benedikt M J LamplRegensburg Department of Public Health, 93059 Regensburg, Germany.ORCID 0000-0002-1008-7934
Matthias PreglerRegensburg Department of Public Health, 93059 Regensburg, Germany.
Hans Helmut NillerInstitute of Medical Microbiology and Hygiene, University of Regensburg, 93053 Regensburg, Germany.
Jonathan JantschInstitute of Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany.
André GessnerInstitute of Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany.
Yvonne EberhardtCenter for Clinical Studies, University Hospital Regensburg, 93053 Regensburg, Germany.
Gunnar HuppertzCenter for Clinical Studies, University Hospital Regensburg, 93053 Regensburg, Germany.
Torsten SchrammCenter for Clinical Studies, University Hospital Regensburg, 93053 Regensburg, Germany.
Stefanie KühnCenter for Clinical Studies, University Hospital Regensburg, 93053 Regensburg, Germany.
Michael KollerCenter for Clinical Studies, University Hospital Regensburg, 93053 Regensburg, Germany.
Thomas DraschDepartment of Nephrology, University Hospital Regensburg, 93053 Regensburg, Germany.
Yvonne EhrlDepartment of Nephrology, University Hospital Regensburg, 93053 Regensburg, Germany.
Bernhard BanasDepartment of Nephrology, University Hospital Regensburg, 93053 Regensburg, Germany.ORCID 0000-0003-2076-2195
Robert OffnerInstitute of Clinical Chemistry and Laboratory Medicine, Department of Transfusion Medicine, University Hospital Regensburg, 93053 Regensburg, Germany.
Barbara SchmidtInstitute of Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany.
Miriam C BanasDepartment of Nephrology, University Hospital Regensburg, 93053 Regensburg, Germany.
University Hospital Regensburg · DEInstitute of Medical Microbiology and Hygiene · DEUniversity of Cologne · DEUniversity of Regensburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

More than 40 human cases of severe encephalitis caused by Borna disease virus 1 (BoDV-1) have been reported to German health authorities. In an endemic region in southern Germany, we conducted the seroepidemiological BoSOT study ("BoDV-1 after solid-organ transplantation") to assess whether there are undetected oligo- or asymptomatic courses of infection. A total of 216 healthy blood donors and 280 outpatients after solid organ transplantation were screened by a recombinant BoDV-1 ELISA followed by an indirect immunofluorescence assay (iIFA) as confirmatory test. For comparison, 288 serum and 258 cerebrospinal fluid (CSF) samples with a request for tick-borne encephalitis (TBE) diagnostics were analyzed for BoDV-1 infections. ELISA screening reactivity rates ranged from 3.5% to 18.6% depending on the cohort and the used ELISA antigen, but only one sample of a patient from the cohort with requested TBE diagnostics was confirmed to be positive for anti-BoDV-1-IgG by iIFA. In addition, the corresponding CSF sample of this patient with a three-week history of severe neurological disease tested positive for BoDV-1 RNA. Due to the iIFA results, all other results were interpreted as false-reactive in the ELISA screening. By linear serological epitope mapping, cross-reactions with human and bacterial proteins were identified as possible underlying mechanism for the false-reactive ELISA screening results. In conclusion, no oligo- or asymptomatic infections were detected in the studied cohorts. Serological tests based on a single recombinant BoDV-1 antigen should be interpreted with caution, and an iIFA should always be performed in addition.

Indexed as

Borna DiseaseBorna disease virusEncephalitisEncephalitis, Tick-BorneEncephalitis, ViralFlavivirus InfectionsAnimalsGermanyHumansBorna disease virus 1 (BoDV-1)diagnosticsELISAencephalitisendogenous Borna-like elementsepidemiologyindirect immunofluorescence assay (iIFA)linear epitope mappingmolecular mimicrysolid organ transplantation

Identifiers

PMID36680228
PMCPMC9867173
OpenAlexW4317242998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.